Eager capital prompts IPO plans for more Chinese makers of brain-computer interfaces

The push by Chinese BCI makers like Arfysica and Neuracle towards IPOs on the Star Market points to a strategic effort to capitalize on domestic capital and foster indigenous high-tech development. This is not just about individual company growth; it reflects China's ambition to build self-sufficiency in critical emerging technologies, mirroring the broader pattern of hi-tech firms listing on the Star Market. The backing from entities like the state-owned National SME Development Fund for Arfysica’s 160 million yuan round underscores the government’s role in directing capital to strategic sectors. Our view is that while the BCI sector is in its early stages, the rapid move to public markets in China could accelerate R&D and commercialization. The risk lies in potential overvaluation given the nascent stage of the technology and the long development cycles involved. For Asia, this means China is positioning itself as a key player in BCI, potentially creating a competitive landscape with Western counterparts like Neuralink, and driving talent and investment within its borders.